A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

The Journal of Clinical Psychiatry
R L RudolphA T Derivan

Abstract

We examined the efficacy and safety of three different dosages of venlafaxine hydrochloride (75, 225, and 375 mg/day) in a multicenter, randomized, double-blind, placebo-controlled, four-group study. Outpatients, 18 to 65 years old, who met DSM-III criteria for major depression were included (N = 358 randomized; 194 completed). Of the total patients completing the trial, 59%, 56%, 51%, and 51% were in the placebo, 75-mg, 225-mg, and 375-mg groups, respectively. The primary outcome measures were the Hamilton Rating Scale for Depression (HAM-D21) total, HAM-D21 depression item, Montgomery-Asberg Depression Rating Scale total, and Clinical Global Impressions scale. Each dosage of venlafaxine was associated with statistically significant improvement as compared with placebo, based on the intent-to-treat sample. The two higher dosages were associated with a modestly greater antidepressant response than was the 75-mg dosage. Nausea, dizziness, somnolence, and anorexia were the most common adverse events attributable to venlafaxine. Since headache occurred at a similar frequency in both the drug and placebo groups, we did not consider it to be attributable to venlafaxine use. Withdrawal from the study due to adverse events occurred in...Continue Reading

Citations

May 4, 2005·European Archives of Psychiatry and Clinical Neuroscience·Mazda AdliMichael Bauer
Jul 28, 2011·Wiener medizinische Wochenschrift·Claudia RessChristoph F Ebenbichler
May 17, 2005·Neuroscience and Biobehavioral Reviews·Alan Frazer, David A Morilak
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Brian J Jones, Thomas P Blackburn
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·S Preskorn
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·S A Montgomery
Dec 22, 2005·Experimental and Clinical Psychopharmacology·Paul M CinciripiniJohn D Minna
Dec 16, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Juan Undurraga, Ross J Baldessarini
Jan 27, 2006·International Clinical Psychopharmacology·Stuart A Montgomery
Mar 27, 2009·Psychotherapy and Psychosomatics·Bret R RutherfordSteven P Roose
Mar 8, 2005·PharmacoEconomics·José-Luis FernandezClément Francois
Jul 24, 2004·CNS Drugs·Jose C AppolinarioWalmir Coutinho
Mar 21, 2009·Social Psychiatry and Psychiatric Epidemiology·Stefan BegréRoland von Känel
Jun 16, 2006·Expert Opinion on Drug Safety·Roger S McIntyreSidney H Kennedy
Jul 13, 2006·Current Medical Research and Opinion·Larry Culpepper
Oct 31, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Thomas C BaghaiHans-Jürgen Möller
Oct 2, 2012·Journal of Anxiety Disorders·Frank J FarachPeter P Roy-Byrne
May 3, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·Martin BaresCyril Höschl
Mar 11, 2008·European Psychiatry : the Journal of the Association of European Psychiatrists·Stefan BegréRoland von Känel
May 25, 2005·Human Psychopharmacology·M LaderT Baekdal
Sep 14, 2010·Acta Psychiatrica Scandinavica·Y-B SchuelerS Weinmann
Dec 3, 2003·Seminars in Cutaneous Medicine and Surgery·Chai Sue Lee, John Koo
Nov 3, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Gilles BertschyFrançois Ferrero
Jul 21, 2004·Psychiatry Research·Ariane Marie-MitchellStanley P Azen
Jan 31, 2006·Archives of Physical Medicine and Rehabilitation·Donald J FosterLumy Sawaki
Feb 18, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sidney H KennedyUNKNOWN Agomelatine Study Group
Mar 6, 2012·Journal of Affective Disorders·Bret R RutherfordSteven P Roose
Apr 23, 2014·Journal of Korean Medical Science·Eunsoo WonUNKNOWN Clinical Research Center for Depression
Jun 10, 2016·Expert Opinion on Pharmacotherapy·Susan L McElroyPaul E Keck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.